dolasetron has been researched along with Vomiting in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (58.18) | 18.2507 |
| 2000's | 21 (38.18) | 29.6817 |
| 2010's | 2 (3.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballinari, G; Barbour, SY; Cox, D; Morrow, GR; Schwartzberg, L; Thorn, MD | 1 |
| Adams, LM; Johnson, B; Kirby, LC; Lebowitz, P; Stoltz, R; Yue, L; Zhang, K | 1 |
| Trepanier, L | 1 |
| Markman, M | 1 |
| Steiner, MA; Theisen, J; Vermeulen, LC; Yorgason, RZ | 1 |
| Tan, M | 1 |
| Cartmell, A; Charu, V; Eisenberg, P; Figueroa-Vadillo, J; Grunberg, S; Hajdenberg, J; Macciocchi, A; Zamora, R | 1 |
| Grunberg, SM; Koeller, JM | 1 |
| Seth, R; Tan, M; Xu, R | 1 |
| Eberhart, LH; Geldner, G; Hoerle, S; Morin, AM; Wulf, H | 1 |
| Rubenstein, EB | 1 |
| Olver, IN | 1 |
| Cartwright, J; Frangoul, H; Ho, RH; Jones, E; Koyama, T; Kuttesch, J; Shankar, S; Whitlock, JA | 1 |
| Awab, A; Chaudhary, L; Hamadani, M; Tfayli, A | 1 |
| Arnold, D; Grothey, A; Hinke, A; Jordan, K; Schmoll, HJ; Voigt, W; Wolf, HH | 1 |
| McNulty, R | 1 |
| Wilkes, G | 1 |
| Awan, FT; Chaudhary, L; Hamadani, M; Khan, JK; Kojouri, K; Ozer, H; Tfayli, A | 1 |
| Catimel, G; Clavel, M; Dumortier, A; Guastalla, JP; Merrouche, Y; O'Grady, P; Rebattu, P | 1 |
| Cappelaere, P; Chauvergne, J; Chevallier, B; Conroy, T; Fabbro, M; Fauser, AA; Goupil, A; Schneider, M; Spielmann, M; Splinter, TA | 1 |
| Baltzer, L; Gralla, RJ; Grunberg, SM; Hahne, WF; Kris, MG; Lifsey, D; Schmidt, L; Tyson, LB; Zaretsky, SA | 1 |
| Aapro, M; Alberto, P; Boyce, M; Busch, B; Kirchner, V; O'Grady, P | 1 |
| Cramer, MB; Facada, A; Gandara, DR; Hahne, WF; Hesketh, AM; Hesketh, PJ; Martin, LA; Perez, EA; Webber, LM | 1 |
| Cramer, MB; Hahne, WF; Hainsworth, JD; Harman, GS; Omura, GA; Ryan, K | 1 |
| Alon, E; Biro, P | 1 |
| Anthony, L; Benedict, C; Gralla, R; Grote, T; Hahne, W; Hainsworth, J; Hesketh, P; Khojasteh, A; Kris, M; Navari, R; Tapazoglou, E | 1 |
| Brawley, OW; Cheson, BD; Phillips, PH | 1 |
| Bey, P; Bourdin, S; Claverie, N; Hahne, W; Le Floch, O; Resbeut, M; Wilkinson, PM | 1 |
| Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA | 1 |
| Alberts, DS; Bertoli, L; Cramer, MB; Eisenberg, P; Hahne, WF; Khojasteh, A; Modiano, MR; Plezia, P; Yeilding, A | 1 |
| Bastit, P; Cals, L; Cappelaere, P; Catimel, G; Chevallier, B; Claverie, N; Fabbro, M; Giovannini, M; Khayat, D; Splinter, T; Wendling, JL | 1 |
| Brown, RA; Graczyk, SG; Hahne, WF; Hickok, CB; Kallar, S; McKenzie, R; Melson, T; Morrill, B | 1 |
| Bradburn, BG; Brown, RA; D'Hollander, A; Diemunsch, P; Feiss, P; Hahne, WF; Leeser, J; Navé, S; Panouillot, P; Paxton, D; Whitmore, J | 1 |
| Aranda, E; Auclerc, G; Audhuy, B; Benhammouda, A; Bleiberg, H; Cals, L; Cappelaere, P; Cattan, A; Cervantes, A; Chevallier, B; Claverie, N; Conroy, T; Cupissol, D; De Grève, J; Diaz-Rubio, E; Fabbro, M; Faraldi, M; Khayat, D; Martin, M; Rivière, A; Seitz, JF | 1 |
| Chin, C; Dempsey, E; Guevin, RM; Hainsworth, J; Hoskins, P; Krook, JE; Lofters, WS; Moquin, JP; Navari, R; Palmer, M; Pater, JL; Verma, S; Walde, D; Wilson, K; Zee, B | 2 |
| Allman, DS; Baker, TW; Chernoff, SB; Ferguson, BB; Fernando, IJ; Grote, TH; Kris, MG; Navari, RM; Nelson, AM; Pendergrass, KB; Pizzo, BA; Thomas, V | 1 |
| Bischoff, M; Fauser, AA; Russ, W | 1 |
| Balfour, JA; Goa, KL | 1 |
| Brown, RA; D'Hollander, A; Diemunsch, P; Hahne, WF; Navé, S; Paxton, L; Schoeffler, P; Wessel, P | 1 |
| Brown, R; Clergue, F; Feiss, P; Hahne, W; Korttila, K; Leeser, J; Nave, S; Olthoff, D; Payeur-Michel, C; Wessel, P | 1 |
| Boerner, TF; Brown, RA; Chelly, JE; Goldberg, ME; Hahne, WF; Hantler, CB; Kovac, AL; Scuderi, PE | 1 |
| Belo, S; Cole, C; Finegan, BA; Knox, D; Perreault, L; Warriner, CB | 1 |
| Brown, RA; Diemunsch, P; Hahne, WF; Helmers, JH; Korttila, K; Leeser, J; Navé, S; Radke, AJ; Wilkey, B | 1 |
| Cramer, MB; DuBois, DM; Grote, TH; Hahne, WF; Hesketh, PJ; Kris, MG; Whitmore, JB | 1 |
| Barr, R; Coppes, MJ; Dempsey, E; Grant, R; Greenberg, ML; Howard, DR; Ingram, LC; Lau, R; Leclerc, JM; Perrotta, M; Wiernikowski, JT | 1 |
| Kovac, A; Mingus, M; Neary, M; Sung, YF | 1 |
| Fauser, AA; Khayat, D; Pizzocaro, G; Schueller, J; Wilkinson, P | 1 |
| Becker, HG; Best, B; Danner, K; Madler, C | 1 |
| Bubalo, J; Karbowicz, S; Maziarz, RT; Seelig, F | 1 |
| Keefe, DL | 1 |
| Gandara, DR; Hesketh, PJ | 1 |
11 review(s) available for dolasetron and Vomiting
| Article | Year |
|---|---|
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indoles; Metoclopramide; Nausea; Ondansetron; Prochlorperazine; Quinolizines; Quinuclidines; Ranitidine; Sucralfate; Vomiting; Weight Loss | 2010 |
Progress in preventing chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Granisetron; Humans; Indoles; Nausea; Neurotransmitter Agents; Ondansetron; Quinolizines; Vomiting | 2002 |
Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Granisetron; Humans; Indoles; Nausea; Ondansetron; Quinolizines; Serotonin Antagonists; Vomiting | 2003 |
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Indoles; Isoquinolines; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2003 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Dexamethasone; Female; Half-Life; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Protein Binding; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2004 |
Update on anti-emetics for chemotherapy-induced emesis.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Australia; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Neoplasms; Ondansetron; Palonosetron; Patient Satisfaction; Prognosis; Quality of Life; Quinolizines; Quinuclidines; Treatment Outcome; Tropisetron; Vomiting | 2005 |
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indoles; Ondansetron; Quinolizines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Tropisetron; Vomiting | 2007 |
[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Topics: Antiemetics; Clinical Trials as Topic; Dose-Response Relationship, Drug; Granisetron; Humans; Indoles; Infusions, Intravenous; Nausea; Ondansetron; Postoperative Complications; Quinolizines; Serotonin Antagonists; Tropisetron; Vomiting | 1996 |
Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Topics: Administration, Oral; Age Factors; Antiemetics; Dexamethasone; Humans; Indoles; Injections, Intravenous; Metoclopramide; Nausea; Postoperative Complications; Quinolizines; Radiotherapy; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Sex Factors; Vomiting | 1997 |
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Vomiting | 1998 |
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Electrocardiography; Granisetron; Heart Failure; Humans; Indoles; Middle Aged; Nausea; Neoplasms; Ondansetron; Quinolizines; Serotonin Antagonists; Vomiting | 2002 |
31 trial(s) available for dolasetron and Vomiting
| Article | Year |
|---|---|
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2014 |
Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.
Topics: Adolescent; Adult; Antiemetics; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Granisetron; Humans; Indoles; Male; Middle Aged; Nausea; Piperazines; Piperidines; Quinolizines; Vomiting; Young Adult | 2009 |
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinolizines; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vomiting | 2003 |
Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
Topics: Antiemetics; Drug-Related Side Effects and Adverse Reactions; Female; Granisetron; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; United States; Vomiting | 2004 |
Droperidol and dolasetron alone or in combination for prevention of postoperative nausea and vomiting after vitrectomy.
Topics: Aged; Anesthesia, General; Antiemetics; Choroidal Neovascularization; Double-Blind Method; Droperidol; Drug Therapy, Combination; Female; Humans; Indoles; Male; Middle Aged; Nausea; Postoperative Complications; Quinolizines; Retinal Diseases; Safety; Vitrectomy; Vomiting | 2004 |
A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Diarrhea; Female; Headache; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Vomiting | 1994 |
Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
Topics: Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Nausea; Quinolizines; Serotonin Antagonists; Vomiting | 1994 |
Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Vomiting | 1993 |
Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Indoles; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Pilot Projects; Quinolizines; Vomiting | 1996 |
A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Nausea; Proportional Hazards Models; Quinolizines; Serotonin Antagonists; United States; Vomiting | 1996 |
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Quinolizines; Remission Induction; Serotonin Antagonists; United States; Vomiting | 1996 |
A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Double-Blind Method; Female; Humans; Indoles; Injections, Intravenous; Linear Models; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Radiotherapy, High-Energy; Treatment Outcome; Vomiting | 1996 |
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; Indoles; Logistic Models; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Patient Satisfaction; Quinolizines; Risk Factors; Therapeutic Equivalency; Vomiting | 1996 |
Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Blood Pressure; Cisplatin; Diarrhea; Double-Blind Method; Drug Tolerance; Electrocardiography; Female; Headache; Heart Rate; Humans; Indoles; Injections, Intravenous; Male; Middle Aged; Patient Satisfaction; Quinolizines; Remission Induction; Safety; Vomiting | 1996 |
A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Topics: Acute Disease; Alcoholism; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Cisplatin; Double-Blind Method; Female; Headache; Humans; Indoles; Injections, Intravenous; Male; Metoclopramide; Middle Aged; Nausea; Neoplasms; Patient Satisfaction; Quinolizines; Remission Induction; Safety; Serotonin Antagonists; Sex Factors; Vomiting | 1997 |
Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery.
Topics: Adult; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Female; Genitalia, Female; Humans; Indoles; Injections, Intravenous; Laparoscopy; Nausea; Patient Satisfaction; Postoperative Complications; Quinolizines; Vomiting | 1997 |
Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Indoles; Injections, Intravenous; Male; Middle Aged; Nausea; Postoperative Complications; Quinolizines; Serotonin Antagonists; Vomiting | 1997 |
A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Granisetron; Humans; Indoles; Male; Middle Aged; Nausea; Quinolizines; Serotonin Antagonists; Vomiting | 1996 |
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Antiemetics; Female; Humans; Indoles; Nausea; Ondansetron; Quinolizines; Serotonin Antagonists; Vomiting | 1997 |
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Topics: Acute Disease; Administration, Oral; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Vomiting | 1997 |
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Injections, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Premedication; Quality of Life; Quinolizines; Vomiting | 1997 |
Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
Topics: Adolescent; Adult; Analysis of Variance; Antiemetics; Double-Blind Method; Female; Genital Diseases, Female; Humans; Indoles; Injections, Intravenous; Middle Aged; Nausea; Postoperative Complications; Quinolizines; Serotonin Antagonists; Treatment Outcome; Vomiting | 1997 |
Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Indoles; Injections, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Postoperative Complications; Quinolizines; Serotonin Antagonists; Vomiting | 1997 |
Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Humans; Indoles; Injections, Intravenous; Logistic Models; Male; Nausea; Patient Satisfaction; Postoperative Complications; Quinolizines; Vomiting | 1997 |
Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hysterectomy; Indoles; Middle Aged; Nausea; Postoperative Complications; Quinolizines; Vomiting | 1997 |
Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Indoles; Middle Aged; Nausea; Postoperative Complications; Quinolizines; Vomiting | 1998 |
Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Area Under Curve; Child; Child, Preschool; Female; Humans; Indoles; Infusions, Intravenous; Male; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Vomiting | 1999 |
Reduced resource utilization in patients treated for postoperative nausea and vomiting with dolasetron mesylate. MCPR44 Study Group.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Health Resources; Humans; Indoles; Male; Nausea; Postoperative Care; Quinolizines; Recovery Room; Vomiting | 1999 |
A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
Topics: Adult; Analysis of Variance; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Logistic Models; Male; Middle Aged; Nausea; Neoplasms; Patient Satisfaction; Quinolizines; Statistics, Nonparametric; Treatment Outcome; Vomiting | 2000 |
[Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
Topics: Administration, Oral; Antiemetics; Double-Blind Method; Droperidol; Female; Humans; Indoles; Infusions, Intravenous; Male; Nausea; Placebos; Postoperative Complications; Quinolizines; Thyroidectomy; Vomiting | 2001 |
Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation.
Topics: Adult; Antiemetics; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Male; Middle Aged; Nausea; Prospective Studies; Quinolizines; Therapeutic Equivalency; Transplantation Conditioning; Vomiting | 2001 |
13 other study(ies) available for dolasetron and Vomiting
| Article | Year |
|---|---|
Patient outcomes after therapeutic interchange of dolasetron for granisetron.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cohort Studies; Female; Granisetron; Humans; Indoles; Male; Middle Aged; Nausea; Quinolizines; Therapeutic Equivalency; Treatment Outcome; United States; Vomiting | 2003 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Tropisetron; Vomiting | 2005 |
Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confusion; Dexamethasone; Diphenhydramine; Drug Therapy, Combination; Female; Granisetron; Humans; Indoles; Infusion Pumps; Infusions, Intravenous; Length of Stay; Lorazepam; Male; Mood Disorders; Ondansetron; Patient Acceptance of Health Care; Quinolizines; Retrospective Studies; Self Administration; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Vomiting | 2007 |
Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Topics: Antiemetics; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Organoplatinum Compounds; Palonosetron; Quinolizines; Quinuclidines; Treatment Outcome; Vomiting | 2006 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Therapeutic Equivalency; Vomiting | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Granisetron; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Platinum Compounds; Quinolizines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2007 |
Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Treatment Outcome; Vomiting | 1994 |
Clinical trials referral resource. Cancer chemoprevention and control trials.
Topics: Analgesics; Anorexia; Antiemetics; Antineoplastic Agents; Behavior Therapy; Cachexia; Cisplatin; Clinical Trials as Topic; Dexamethasone; Drug Combinations; Humans; Indoles; Megestrol; Megestrol Acetate; Neoplasms; Pain, Intractable; Pilot Projects; Quinolizines; Vomiting; Vomiting, Anticipatory | 1996 |
Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; Indoles; Male; Nausea; Pilot Projects; Quinolizines; Transplantation Conditioning; Vomiting; Whole-Body Irradiation | 1997 |
Approval of dolasetron expands antiemetic choices.
Topics: Antiemetics; Antineoplastic Agents; Drug Approval; Humans; Indoles; Quinolizines; United States; United States Food and Drug Administration; Vomiting | 1998 |
Dolasetron for prevention of nausea and vomiting due to cancer chemotherapy.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Vomiting | 1998 |
Serotonin antagonists: a new class of antiemetic agents.
Topics: Antiemetics; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Granisetron; Humans; Imidazoles; Indazoles; Indoles; Metoclopramide; Ondansetron; Quinolizines; Receptors, Serotonin; Serotonin Antagonists; Tropanes; Tropisetron; Vomiting | 1991 |